Compare FormFactor Inc. FormFactor Inc. Common Stock (FORM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FormFactor Inc. FormFactor Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? FormFactor Inc. FormFactor Inc. Common Stock trades at $115 (market cap $10.01B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: FormFactor Inc. FormFactor Inc. Common Stock is far larger — about 2.7× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 1,445,909). Which is the better fit depends on your goals — on Pluang, investors hold FormFactor Inc. FormFactor Inc. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| FORM | TNGX | |
|---|---|---|
Market Cap | $10.01B | $3.75B |
Volume | 1,445,909 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $159.93 | $32.90 |
52-Week Low | $41.29 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.69B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FormFactor (FORM) trades at $128.09, down 1.68% on the day, amid a bullish technical setup with key support at $127. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28. Revenue and net income are projected to grow significantly in 2026, though valuation ratios remain elevated.
The outlook is positive, driven by strong AI-driven semiconductor demand and strategic collaborations, but high P/E and P/S ratios pose valuation risks. Analyst consensus is bullish with a $154.71 price target, though insider selling and negative cash flow in 2025 warrant caution.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FormFactor Inc. FormFactor Inc. Common Stock
FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.
Read more on FORM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
